drugset
Drugs / RTS,S/AS01E
last change Oct 2021 re-read 3 minutes ago

RTS,S/AS01E

Vaccine

Developed for
malaria
Investigated by
GlaxoSmithKline · The PATH Malaria Vaccine Initiative (MVI)

Trials 1

today NCT03162614 · Ph 2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03162614 May 2017 → Jul 2018 malaria GlaxoSmithKline Completed Met primary

Press releases naming this drug 2 releases

DateIssuerRelease
2021-10-06 GlaxoSmithKline GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine gsk.com ↗
2021-01-27 GlaxoSmithKline GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine gsk.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RTS,S/AS01E ClinicalTrials.gov intervention name — accepted as the source's own label NCT03162614 ↗
Modality Vaccine “candidate malaria vaccines RTS,S/AS01B (adult formulation) and RTS,S/AS01E (pediatric formulation)” NCT03162614 ↗
Route Intramuscular “Subjects will receive intramuscular injection of RTS,S/AS01E.” NCT03162614 ↗